Approval · Notice of Compliance 28020 · 2022
SPIRIVA: Notice of Compliance 28020
Issued April 25, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28020
- Date
- April 25, 2022
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update the Warnings and Precautions sections of the Product Monograph Update the Patient Medication Information sections of the Product Monograph Convert Product Monograph to 2020 format Update the package insert Update the inner and outer labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SPIRIVA | Not yet assigned | — |
Medicinal ingredients
- TIOTROPIUM BROMIDE MONOHYDRATE 18 MCG per CAP